Phase 2 Lymphoma Trial, Recruiting NCT05583071 Sponsor: University of Cologne Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT05583071
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 69 with a reduced ability to carry out daily activities (as assessed by their doctor), or people aged 70 and older, who are not suitable for a stem cell transplant in their doctor's judgment
  • People who have been newly diagnosed with a type of brain cancer called primary B-cell lymphoma of the central nervous system (PCNSL), confirmed by a biopsy or fluid sample, and who have not yet received treatment for it
  • People who have at least one measurable area of disease that can be tracked during the trial
  • People whose kidneys, liver, bone marrow, heart, and lungs are functioning at an adequate level as assessed by blood tests and other checks
  • People who have read, understood, and signed a consent form agreeing to take part in the trial
  • Women who are past menopause, cannot become pregnant, or who agree to use an approved form of contraception during the trial
  • Men whose partners could become pregnant and who agree to use an approved form of contraception during the trial

Who may not be able to join:

  • People who have already received treatment for PCNSL, beyond a short initial course of steroids and/or a single dose of certain chemotherapy drugs (rituximab and/or methotrexate)
  • People whose lymphoma has spread to parts of the body outside the brain or spinal cord
  • People who have previously been diagnosed with any other type of non-Hodgkin lymphoma at any point in their life
  • People whose lymphoma is only in the eye or the lining of the brain/spinal cord, with no involvement of the brain tissue or spinal cord itself
  • People who have HIV infection
  • People who have or have had another cancer, unless it was completely cured by surgery or there has been no sign of the cancer for at least 5 years
  • People who have a known allergy or sensitivity to any of the study medications or their ingredients
  • People who have mouth sores or stomach/gut ulcers that would make it unsafe to use methotrexate
  • People who have an active hepatitis B, C, or E infection confirmed by a blood test
  • People who have a serious active infection
  • People who have a weakened immune system due to a medical condition or a previous organ transplant
  • Women who are pregnant or currently breastfeeding
  • People who are not able to understand what the trial involves or make their own informed decisions about taking part
  • People who may not be able to follow the trial requirements, for example due to heavy alcohol use, drug dependency, refusal of blood products, or other circumstances that would make completing the trial difficult
  • People who have an employment or dependent relationship with the organisation or doctor running the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +49221478

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Cologne
Registry
ClinicalTrials.gov
Start date
23 August 2024
Est. completion
1 February 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

complete response rate (CRR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov